Arkolith/Insider Trading/OTLC/Form 4

Trieu Vuong

CHAIRMAN AND CEO, Director, 10% OwnerOncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Jun 30, 2023
Net Buying
Open-Market Buys
$11K
Open-Market Sells
$0
Net Open-Market Flow
$11K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 29, 2023Buy(P)425K$0.02$9K92.0M
Jun 28, 2023Buy(P)75K$0.03$2K91.6M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-23-023015) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML